UNSPSC 51282312: Erythromycin a

This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63937KV33D, chemically known as erythromycin estolate impurity, free erythromycin-, but more generally known as erythromycin a, which bears US NIH Compound Identifier 3255. European Medicines Agency schedules erythromycin a or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG.

Most nations, for tariff purposes, schedule erythromycin a under HS 29415000. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.

UNSPSC 51282312 Erythromycin A is a Commodity code whose recent activity shows minimal alignment with state and local pharmaceutical procurement. The single pharmaceutical-adjacent solicitation in the recent record, a Texas HHS Commission Request for Information on direct-to-manufacturer prescription programs, concerns pharmacy benefit architecture rather than specific drug acquisition. The remaining recent opportunities tagged under this code—Seminole County's bid for Naloxone and drug deactivation systems, Tampa Fire Department's medical and first aid supplies procurement, and the Minnesota Multistate Cooperative Purchasing Alliance generic pharmaceutical framework—address emergency medical supplies, rescue operations consumables, and broad-spectrum OTC and generic drug distribution respectively, none of which center on erythromycin or antibiotics as a category. The mismatch between the code's nominal scope and actual recent buying signals suggests either miscoding in the sourcing systems or very limited recent demand for erythromycin specifically under this UNSPSC designation.

The geographic footprint of recent activity spans Florida (Seminole County, Tampa), Texas (HHS Commission), and Minnesota (MMCAP serving state and local entities across multiple jurisdictions including Oregon), but these opportunities reflect emergency response inventory, cooperative purchasing frameworks for generics and OTC products, and pharmacy program restructuring rather than targeted antibiotic procurement. No issuing body has issued a recent RFP, RFQ, IFB, or ITB explicitly requesting erythromycin acquisition. Unless state and local procurement offices are routinely miscoding antibiotic buys, this code shows little decision-relevant recent activity for business development targeting pharmaceutical manufacturers or distributors of erythromycin to state and local customers.